Is BridgeBio Pharma Inc (BBIO) a risky stock?
As of July 23, 2026, Clavix grades BridgeBio Pharma Inc (BBIO) C+ for risk, a composite score of 65 out of 100 on an A+ to F scale, which puts BBIO in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 23, 2026. Clavix regrades every trading day.
The five risk dimensions behind BBIO's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how BBIO scores on each, as of July 23, 2026.
What's moving BBIO's risk right now
Company-specific signals Clavix flags behind BBIO's current grade, drawn from recent news and filings as of July 23, 2026.
Guidance cuts or consensus estimate reductions signal near-term earnings pressure that typically precedes multiple contraction.
Fifth Third Bancorp purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the first quarter, according to the company in its most recent…
A meaningful insider divestiture of nearly $1.44M by a board director at a price of $84/share, which may draw investor attention to insider news signal, though the director still ma…
Recent BBIO news
The latest headlines Clavix ingested for BridgeBio Pharma Inc, newest first. These feed the news-sentiment dimension of BBIO's grade.
-
Citigroup raised its price target on BridgeBio Pharma (BBIO) from $82.00 to $93.00, maintaining a neutral rating, as part of broader analyst EPS estimate updates for July 16th.
What a C+ grade means
On the Clavix A+ to F scale, BBIO's composite of 65 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell BBIO or any security. Grades are risk indicators, not predictions of return. Data may be delayed.